Pharmacovigilance Opportunities in the MENA Region

Webinar: Pharmacovigilance Opportunities in the MENA Region

Pharmacovigilance is getting more and more attention in MENA countries thanks to new regulations and steps in the right direction. The MENA region itself holds great promise for the pharmaceutical industry, being potentially hugely profitable. Together these 22 countries have a 350 million population that spends over $30 billion on pharmaceutical products per year and show robust growth. However, it is not a simple task to enter this market due to various factors, including the lack of a centralized pharmaceutical regulator. So how do you effectively guarantee pharmacovigilance in a region that shows significant differences in pharmacovigilance maturity at the country level?

Ensuring drug safety in MENA?

Let’s talk how we can team up to manage your pharmacovigilance activities in the emerging markets.

Who Should Attend?

Professionals from drug safety:

  • Global QPPVs / Deputies
  • QPPV Office managers
  • Heads of Pharmacovigilance
  • Heads of Pharmacovigilance Technologies
  • Drug Safety Managers and Leaders

Duration: 1 hour.

Speakers:

  • Martijn van de Leur, Head of Global Pharmacovigilance
  • Albert Bekfi, Head of Pharmacovigilance Operations
Martijn van de Leur

Martijn van de Leur

Head of Global Pharmacovigilance

Other content that might interest you:

No Results Found

The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.

Local Literature Surveillance Challenges and Specifics in the EU, CIS and LATAM regions

Local Literature Surveillance Challenges and Specifics in the EU, CIS and LATAM regions

PV legislation introduced by the European Commission in 2012 and GVP guidelines together with local requirements committed each MAH to perform literature review in countries where their products are present. Compliance with mandatory requirements and guidelines is not always a simple task when local requirements and specifics come along. In this article, we will take a closer look at these challenges and specifics for local literature surveillance in different regions as EU, CIS and LATAM.

read more
Remaining Vigilant and Compliant after Brexit: What’s next? (Latest Updates)

Remaining Vigilant and Compliant after Brexit: What’s next? (Latest Updates)

On 29th March 2017 UK submitted the notification of its intention to withdraw from the EU. This means that UK will become a ‘third country’ from 30th March’19. Even though leaving the EU with a deal remains the Government’s top priority, UK drug agency is publishing a series of guidance documents for industry and other stakeholders covering the proposed arrangements for the regulation of medicines, medical devices and clinical trials, if UK leaves EU with no deal.

read more
Harmonization of EAEU GVP: CIS is getting more vigilant than ever before

Harmonization of EAEU GVP: CIS is getting more vigilant than ever before

On the 6-7 March, Biomapas Pharmacovigilance Department management and team from the CIS region participated in a meeting in Minsk. It was dedicated to strengthening collaboration between the team members as well as updating knowledge on latest PV trends. We discussed the most recent releases of legislation, such as Eurasian Economic Union Good Pharmacovigilance Practice harmonization and the importance of a teamwork approach with Biomapas’ PV Project Manager CIS, Aliaksandr Bakshtanovich, MD.

read more

Big Enough To Cover  All Your Needs. Small Enough To Care.

Discover the tailored solutions that Biomapas provides to accelerate your clinical trials and optimize your drug development process.

Clinical Research

Regulatory Affairs

Pharmacovigilance

Medical Information